542 related articles for article (PubMed ID: 22284994)
1. Roflumilast: a phosphodiesterase-4 inhibitor for the treatment of severe chronic obstructive pulmonary disease.
Pinner NA; Hamilton LA; Hughes A
Clin Ther; 2012 Jan; 34(1):56-66. PubMed ID: 22284994
[TBL] [Abstract][Full Text] [Related]
2. Roflumilast: a novel treatment for chronic obstructive pulmonary disease.
Reid DJ; Pham NT
Ann Pharmacother; 2012 Apr; 46(4):521-9. PubMed ID: 22433610
[TBL] [Abstract][Full Text] [Related]
3. Roflumilast for the treatment of chronic obstructive pulmonary disease.
Rabe KF
Expert Rev Respir Med; 2010 Oct; 4(5):543-55. PubMed ID: 20649375
[TBL] [Abstract][Full Text] [Related]
4. Roflumilast: doubtful efficacy but clear harms in COPD.
Prescrire Int; 2013 Jan; 22(134):5-9. PubMed ID: 23367674
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of roflumilast in patients with stable chronic obstructive pulmonary disease: a meta-analysis.
Yan JH; Gu WJ; Pan L
Pulm Pharmacol Ther; 2014 Feb; 27(1):83-9. PubMed ID: 23624309
[TBL] [Abstract][Full Text] [Related]
6. Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β2-agonist fixed-dose combination: RE(2)SPOND rationale and study design.
Rennard SI; Martinez FJ; Rabe KF; Sethi S; Pizzichini E; McIvor A; Siddiqui S; Anzueto A; Zhu H
Int J Chron Obstruct Pulmon Dis; 2016; 11():1921-8. PubMed ID: 27574416
[TBL] [Abstract][Full Text] [Related]
7. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial.
Martinez FJ; Calverley PM; Goehring UM; Brose M; Fabbri LM; Rabe KF
Lancet; 2015 Mar; 385(9971):857-66. PubMed ID: 25684586
[TBL] [Abstract][Full Text] [Related]
8. Potential treatment benefits and safety of roflumilast in COPD: a systematic review and meta-analysis.
Yuan L; Dai X; Yang M; Cai Q; Shao N
Int J Chron Obstruct Pulmon Dis; 2016; 11():1477-83. PubMed ID: 27418821
[TBL] [Abstract][Full Text] [Related]
9. The potential role of roflumilast: the new phosphodiesterase-4 inhibitor.
Karish SB; Gagnon JM
Ann Pharmacother; 2006 Jun; 40(6):1096-104. PubMed ID: 16735669
[TBL] [Abstract][Full Text] [Related]
10. Roflumilast--a phosphodiesterase-4 inhibitor licensed for add-on therapy in severe COPD.
Taegtmeyer AB; Leuppi JD; Kullak-Ublick GA
Swiss Med Wkly; 2012; 142():w13628. PubMed ID: 22833385
[TBL] [Abstract][Full Text] [Related]
11. Reduction of exacerbations by the PDE4 inhibitor roflumilast--the importance of defining different subsets of patients with COPD.
Rennard SI; Calverley PM; Goehring UM; Bredenbröker D; Martinez FJ
Respir Res; 2011 Jan; 12(1):18. PubMed ID: 21272339
[TBL] [Abstract][Full Text] [Related]
12. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials.
Calverley PM; Rabe KF; Goehring UM; Kristiansen S; Fabbri LM; Martinez FJ;
Lancet; 2009 Aug; 374(9691):685-94. PubMed ID: 19716960
[TBL] [Abstract][Full Text] [Related]
13. Treatment of chronic obstructive pulmonary disease with roflumilast, a new phosphodiesterase 4 inhibitor.
Gross NJ; Giembycz MA; Rennard SI
COPD; 2010 Apr; 7(2):141-53. PubMed ID: 20397815
[TBL] [Abstract][Full Text] [Related]
14. Roflumilast added to triple therapy in patients with severe COPD: a real life study.
Muñoz-Esquerre M; Diez-Ferrer M; Montón C; Pomares X; López-Sánchez M; Huertas D; Manresa F; Dorca J; Santos S
Pulm Pharmacol Ther; 2015 Feb; 30():16-21. PubMed ID: 25445930
[TBL] [Abstract][Full Text] [Related]
15. Roflumilast : the new orally active, selective phophodiesterase-4 inhibitor, for the treatment of COPD.
Tashkin DP
Expert Opin Pharmacother; 2014 Jan; 15(1):85-96. PubMed ID: 24032576
[TBL] [Abstract][Full Text] [Related]
16. Roflumilast for asthma and chronic obstructive pulmonary disease.
Cowan C
Issues Emerg Health Technol; 2005 Oct; (74):1-4. PubMed ID: 16317827
[TBL] [Abstract][Full Text] [Related]
17. Roflumilast in the management of chronic obstructive pulmonary disease.
Lipari M; Benipal H; Kale-Pradhan P
Am J Health Syst Pharm; 2013 Dec; 70(23):2087-95. PubMed ID: 24249758
[TBL] [Abstract][Full Text] [Related]
18. Reduce disease burden and improve lung function-roflumilast: approved for moderate to severe COPD: update for the clinical nurse specialist.
O'Malley P
Clin Nurse Spec; 2011; 25(4):176-7. PubMed ID: 21654371
[No Abstract] [Full Text] [Related]
19. Roflumilast for severe COPD?
Drug Ther Bull; 2011 Apr; 49(4):45-8; quiz iii-iv. PubMed ID: 21467576
[TBL] [Abstract][Full Text] [Related]
20. Roflumilast: clinical benefit in patients suffering from COPD.
Ulrik CS; Calverley PM
Clin Respir J; 2010 Oct; 4(4):197-201. PubMed ID: 20887341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
